These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37519082)

  • 1. [Immunotherapies in Alzheimer's disease: state of the art and potential use in the elderly].
    Delrieu J; Ousset PJ
    Geriatr Psychol Neuropsychiatr Vieil; 2023 Jun; 21(2):233-240. PubMed ID: 37519082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
    Villain N
    Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?].
    Villain N
    Geriatr Psychol Neuropsychiatr Vieil; 2022 Jun; 20(2):256-260. PubMed ID: 35929392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive Alzheimer's immunotherapy: A promising or uncertain option?
    Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B
    Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease.
    Liu KY; Villain N; Ayton S; Ackley SF; Planche V; Howard R; Thambisetty M
    Brain Commun; 2023; 5(3):fcad175. PubMed ID: 37389302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.
    Wang Y; Yan T; Lu H; Yin W; Lin B; Fan W; Zhang X; Fernandez-Funez P
    Neurodegener Dis; 2017; 17(6):242-250. PubMed ID: 28787714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lecanemab: More Questions Than Answers!
    Kaur U; Reddy J; Tiwari A; Chakrabarti S; Chakrabarti SS
    Clin Drug Investig; 2024 Jan; 44(1):1-10. PubMed ID: 38095822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
    van Dyck CH
    Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from antiamyloid-β immunotherapies in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Handb Clin Neurol; 2023; 193():267-292. PubMed ID: 36803816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.